[Viral validation of the bio-globulin production process]

Area of Science:

• Virology and Biotechnology
• Immunology and Pharmaceutical Manufacturing

Context:

• Intravenous immunoglobulin (IVIG) is a critical therapeutic agent derived from human plasma.
• Ensuring the viral safety of IVIG products is paramount for patient protection.
• Domestic production of IVIG requires rigorous validation of pathogen removal steps.

Purpose:

• To validate the efficacy of the domestic human immunoglobulin manufacturing process in eliminating lipid-enveloped viruses.
• To assess the inactivation of model viruses for Hepatitis B virus (HBV) and Hepatitis C virus (HCV) during production.

Summary:

• The study utilized pseudorabies virus (PR-75, a DNA virus model for HBV) and Sindbis virus (an RNA virus model for HCV) to challenge the IVIG manufacturing process.
• Virus survival was monitored throughout production stages, with pepsin digestion identified as a key step for complete viral inactivation.
• The overall manufacturing process demonstrated a reduction in infective viral titers exceeding 10 logs, confirming robust viral clearance.

Impact:

• Confirms the safety and reliability of domestically produced intravenous immunoglobulin concerning lipid-enveloped viral contamination.
• Provides evidence supporting the effectiveness of specific manufacturing steps, such as pepsin digestion, in viral inactivation.
• Contributes to the assurance of safe biological product manufacturing and patient safety in healthcare.